Starpharma Holdings Limited Stock price

Equities

SPL

AU000000SPL0

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.125 AUD -3.85% Intraday chart for Starpharma Holdings Limited 0.00% -26.47%
Sales 2022 5.16M 3.37M Sales 2023 4.21M 2.75M Capitalization 127M 83.05M
Net income 2022 -16M -10.44M Net income 2023 -15M -9.79M EV / Sales 2022 50.5 x
Net cash position 2022 41.73M 27.23M Net cash position 2023 26.91M 17.56M EV / Sales 2023 23.8 x
P/E ratio 2022
-18.5 x
P/E ratio 2023
-7.75 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 92.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.85%
Current month-7.41%
1 month-3.85%
3 months-30.56%
6 months-26.47%
Current year-26.47%
More quotes
1 week
0.13
Extreme 0.125
0.14
1 month
0.12
Extreme 0.12
0.14
Current year
0.12
Extreme 0.12
0.19
1 year
0.12
Extreme 0.12
0.53
3 years
0.12
Extreme 0.12
2.19
5 years
0.12
Extreme 0.12
2.52
10 years
0.12
Extreme 0.12
2.52
More quotes
Managers TitleAgeSince
Chief Executive Officer - Jan. 07
Director of Finance/CFO - 23-04-02
Corporate Officer/Principal - 13-08-11
Members of the board TitleAgeSince
Director/Board Member - 22-03-31
Chairman 79 13-12-03
Director/Board Member 53 20-02-29
More insiders
Date Price Change Volume
24-03-28 0.125 -3.85% 352,229
24-03-27 0.13 0.00% 59,110
24-03-26 0.13 0.00% 407,099
24-03-25 0.13 +4.00% 84,027
24-03-22 0.125 0.00% 125,174

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Starpharma Holdings Limited - Australian S.E.